Status:
COMPLETED
Effect of Dolutegravir Intensification on HIV-1 Reservoirs
Lead Sponsor:
University of Liege
Conditions:
HIV-1-infection
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Persistent HIV viremia occurs in most ART-treated patients and could arise from reactivation of viral expression from latently-infected cells that constitute the viral latent reservoir (LR) and/or res...
Eligibility Criteria
Inclusion
- HIV-infected adults receiving cART for at least 3 years
- Undetectable viral for at least 3 years
- DTG/3TC/ABC as cART regimen in the previous 6 months.
- CD4 counts higher than 200 cells per μL
Exclusion
- active hepatitis C or B
- unstable liver disease
- renal impairment (estimated glomerular filtration rate \<50 mL per min),
- gastrointestinal disorders that would affect the absorption of study treatment
- current use of drugs with significant interactions with dolutegravir
- current use of drugs with an impact on inflammation such as steroids.
- hospitalization for acute illness within the previous 8 weeks
- Pregnancy or breastfeeding.
- Anal or rectal lesions impeding rectal biopsies
- Decreased platelets count or coagulation disorder.
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 13 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05351684
Start Date
January 1 2019
End Date
December 13 2022
Last Update
December 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Liège university hospital
Liège, Belgium, 4000